

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
9 September 2005 (09.09.2005)

PCT

(10) International Publication Number
WO 2005/082938 A2

(51) International Patent Classification⁷: **C07K 16/00**

(21) International Application Number:
PCT/IT2005/000078

(22) International Filing Date: 16 February 2005 (16.02.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
RM2004A000105 27 February 2004 (27.02.2004) IT

(71) Applicant (for all designated States except US): **TECNO-
GEN S.C.P.A.** [IT/IT]; Località La Fagianeria, I-81013 Pi-
ana di Monte Verna (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DE SANTIS, Rita**
[IT/IT]; c/o Sigma-Tau Industrie, Farmaceutiche Riunite

S.p.A., Via Pontina, Km. 30.400, I-00040 Pomezia (IT).
PELLICCIA, Angela [IT/IT]; c/o Sigma-Tau Industrie,
Farmaceutiche Riunite S.p.A., Via Pontina, Km. 30.400,
I-00040 Pomezia (IT). **PALOMBO, Giovanna** [IT/IT]; c/o
Tecnogen S.c.p.A., Località La Fagianeria, I-81013 Piana
di Monte Verna (IT). **CARMINATI, Paolo** [IT/IT]; c/o
Sigma-Tau Industrie, Farmaceutiche Riunite S.p.A., Via
Pontina, Km. 30.400, I-00040 Pomezia (IT).


(74) Agent: **SPADARO, Marco et al.**; Cavattoni-Raimondi,
Viale dei Parioli, 160, I-00197 Roma (IT).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ,

[Continued on next page]

(54) Title: **ANTI-HUMAN TENASCIN MONOCLONAL ANTIBODY**

Schematic representation of human tenascin-C and of the strategy
followed for the generation of BC2-like antibodies



(57) Abstract: An anti-human
tenascin monoclonal antibody is
described, whose light and heavy chain
variable region sequences are SEQ ID
NO: 1 and SEQ ID NO: 2, respectively,
its proteolytic fragments capable
of binding to an antigenic epitope
within the region A₍₁₋₄₎-D of human
tenascin, its recombinant derivatives,
its conjugates and its similar functional
analogues capable of binding to an
antigenic epitope within the A₍₁₋₄₎-D
region of human tenascin.

Immunisation of Balb/c mice with Tn
(A₁₋₄-D) fragment

Fusion of spleen cells of immunised mice with
Sp2/0 Ag14 myeloma cells

Screening of culture supernatants of hybridomas
obtained on purified tenascin



TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.